Abstract
The aim of this study is to systematically evaluate the efficacy and safety of matrine injection (MI) combined with first-line chemotherapy in the treatment of lung cancer. The search was applied to Cochrane Library, EMBASE, PubMed, Web of Science, CNKI, WANFANG DATA, VIP and CBM database from 2006 to 2016. Randomized controlled trials (RCTs) of MI combining first-line chemotherapy (versus chemotherapy alone) in any language were included. Two authors extracted data and assessed literature quality independently.
Meta-analysis was conducted by using RevMan 5.3 software. Ten studies total 906 cases were included. The meta-analysis showed that compared with the first-line chemotherapy alone, the combination of MI and first-line chemotherapy in the treatment of lung cancer could not only improve the short-term clinical efficacy [RR = 1.17, 95% CI (1.02, 1.34), P = 0.02], complete response (CR) [RR = 1.46, 95% CI (0.99, 2.15), P = 0.06] and the quality of life [RR = 1.62, 95% CI (1.19, 2.20), P = 0.002], but also reduce WBC toxicity [RR = 0.39, 95% CI (0.27, 0.55), P < 0.00001] and the nausea and vomiting [RR = 0.52, 95% CI (0.37, 0.73), P = 0.0002]. Matrine injection combined with first-line chemotherapy regimen for lung cancer has a certain synergistic effect, but it needs to be further confirmed through a large sample of clinical studies.
Keywords
Full Text:
References
Siegel RL, Miller KD, Jemal A, et al. Cancer statistics. CA Cancer J Clin. 2017;67:7–30
Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. China J Cancer Res. 2015;27:2–12.
Fang WG, Cao SL. The new theory and technology of Oncology. Shanghai: science and technology education press. 1997:1020–1030.
Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, et al. Effects of matrine on proliferation and differentiation in K562 cells. Leuk Res. 2001;25:793–800.
Huang ZS, Zhou XH, Wei X, Qin YQ, Su QB, Yin YX. Matrine combined with DDP on human hepatocarcinoma cell line SMMC-7721: apoptosis-inducing effect and its mechanism. Liaoning J Trad Chinese Med. 2008;35:1284–1286.
Li ZR. Pharmacological and clinical research progress of oxymatrine. West China J Pharm Sci. 2003;18:435.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Inter Med. 2009;151:W65–W94.
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Updated March 2011]. The Cochrane Collaboration. http://www. cochrane-handbook. org. 2013.
Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20:448–452.
MK Palmer. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization. 1979;38:484–485.
Yates JW, Chalmer B, Mc-Kegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220–2224.
Zhang JW, Duan DM, Ren ZH. Effect of matrine injection combined with GP regimen in patients with non-small cell lung cancer. Chinese J Exp Trad Med Formulae. 2015;23:184–187.
Zhang ZY, Gao XH, Guo SS, et al. Observation of short-term efficacy of matrine injection combined with NP regimen in the treatment of advanced NSCLC. Shandong Med J. 2011;26:100–101.
Liu JL, Zhou LL, Cai MH. Treatment of advanced non-small cell lung cancer with matrine glucose combined with GP regimen. Chin J Mod Drug Appl. 2011;20:69–70.
Zhou L, Wang LY. Observation of Short-term efficacy of matrine injection combined with NP regimen in the treatment of advanced non-small cell lung cancer. Nurs Prac Res. 2009;24:51–53.
Xu w, Xu YX, Gao W. Observation on curative effect of matrine injection combined with chemotherapy on middle and advanced non-small cell lung cancer. Bull Med Res. 2005;7:62–63.
Yan J. Observation on curative effect of matrine injection in the treatment of advanced malignant tumor. Prac Clin Med. 2001;4:135.
Shi LH, Qiu YH. Clinical Investigation of Kosam combined with chemotherapy to treat advanced malignant tumors. J Chinese Oncol. 2001;2:95–97.
Su SY. Observation of short-term efficacy of matrine injection in the treatment of advanced non-small cell lung cancer. Health World. 2014;22:138.
Tao YJ. Clinical observation on the effect of Sophora flavescens injection on prevention and treatment of lung cancer chemotherapy. J Clin Med Pract. 2007;11:95–96.
Zhu L, Zhang Z. Short-term efficacy of matrine injection in the treatment of advanced non-small cell lung cancer. Guide of China Med. 2016;14:180–181.
Li M, Liao H, Cheng HH. Effects of oxymatrine on the proliferation of human lung cancer A549 cells and the activity of caspase 3/7 protein. Chinese J Cell Mol Immunol. 2013;29:498–499.
Cai Y. Advances in pharmacological effects of oxymatrine. J Prac Trad Chinese Med. 2016;32:387–389.
Refbacks
- There are currently no refbacks.
Copyright (c) 2017 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.